Monika Parisi

Comparative Effectiveness of nab-Paclitaxel Plus Gemcitabine vs FOLFIRINOX in Metastatic Pancreatic Cancer: A Retrospective Nationwide Chart Review in the United States

Sunnie S. Y. Kim, James Signorovitch, Hongbo Yang et al. · Advances in Therapy · 2018 · 89 citations · Full text

Comparison of treatment patterns and economic outcomes among metastatic pancreatic cancer patients initiated on <i>nab</i>-paclitaxel plus gemcitabine versus FOLFIRINOX

Ali McBride, Machaon Bonafede, Qian Cai et al. · Expert Review of Clinical Pharmacology · 2017 · 49 citations

Clinical Outcomes with First-Line Chemotherapy in a Large Retrospective Study of Patients with Metastatic Pancreatic Cancer Treated in a US Community Oncology Setting

Thomas H. Cartwright, Monika Parisi, Janet L. Espirito et al. · Drugs - Real World Outcomes · 2018 · 49 citations · Full text

Comparative effectiveness and resource utilization of &lt;em&gt;nab&lt;/em&gt;-paclitaxel plus gemcitabine vs FOLFIRINOX or gemcitabine for the first-line treatment of metastatic pancreatic adenocarcinoma in a US community setting

Fadi Braiteh, Manish Patel, Monika Parisi et al. · Cancer Management and Research · 2017 · 33 citations · Full text

Comparative effectiveness of early-line &lt;em&gt;nab&lt;/em&gt;-paclitaxel vs. paclitaxel in patients with metastatic breast cancer: a US community-based real-world analysis

Reshma Mahtani, Monika Parisi, Stefan Glück et al. · Cancer Management and Research · 2018 · 33 citations · Full text